Cellular senescence in neuroblastoma.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
02
09
2021
accepted:
10
02
2022
revised:
14
01
2022
pubmed:
25
2
2022
medline:
27
5
2022
entrez:
24
2
2022
Statut:
ppublish
Résumé
Neuroblastoma is a tumour that arises from the sympathoadrenal lineage occurring predominantly in children younger than five years. About half of the patients are diagnosed with high-risk tumours and undergo intensive multi-modal therapy. The success rate of current treatments for high-risk neuroblastoma is disappointingly low and survivors suffer from multiple therapy-related long-term side effects. Most chemotherapeutics drive cancer cells towards cell death or senescence. Senescence has long been considered to represent a terminal non-proliferative state and therefore an effective barrier against tumorigenesis. This dogma, however, has been challenged by recent observations that infer a much more dynamic and reversible nature for this process, which may have implications for the efficacy of therapy-induced senescence-oriented treatment strategies. Neuroblastoma cells in a dormant, senescent-like state may escape therapy, whilst their senescence-associated secretome may promote inflammation and invasiveness, potentially fostering relapse. Conversely, due to its distinct molecular identity, senescence may also represent an opportunity for the development of novel (combination) therapies. However, the limited knowledge on the molecular dynamics and diversity of senescence signatures demands appropriate models to study this process in detail. This review summarises the molecular knowledge about cellular senescence in neuroblastoma and investigates current and future options towards therapeutic exploration.
Identifiants
pubmed: 35197583
doi: 10.1038/s41416-022-01755-0
pii: 10.1038/s41416-022-01755-0
pmc: PMC9130206
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1529-1538Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585–621.
pubmed: 13905658
doi: 10.1016/0014-4827(61)90192-6
Olovnikov AM. [Principle of marginotomy in template synthesis of polynucleotides]. Dokl Akad Nauk SSSR. 1971;201:1496–9.
pubmed: 5158754
Olovnikov AM. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol. 1973;41:181–90.
pubmed: 4754905
doi: 10.1016/0022-5193(73)90198-7
Harley CB. Aging of cultured human skin fibroblasts. Methods Mol Biol. 1990;5:25–32.
pubmed: 21374112
Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279:349–52.
pubmed: 9454332
doi: 10.1126/science.279.5349.349
Faget DV, Ren Q, Stewart SA. Unmasking senescence: context-dependent effects of SASP in cancer. Nat Rev Cancer. 2019;19:439–53.
pubmed: 31235879
doi: 10.1038/s41568-019-0156-2
Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685–705.
pubmed: 23140366
doi: 10.1146/annurev-physiol-030212-183653
Wiley CD, Velarde MC, Lecot P, Liu S, Sarnoski EA, Freund A, et al. Mitochondrial dysfunction induces senescence with a distinct secretory phenotype. Cell Metab. 2016;23:303–14.
pubmed: 26686024
doi: 10.1016/j.cmet.2015.11.011
Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev. 2010;24:2463–79.
pubmed: 21078816
pmcid: 2975923
doi: 10.1101/gad.1971610
Salama R, Sadaie M, Hoare M, Narita M. Cellular senescence and its effector programs. Genes Dev. 2014;28:99–114.
pubmed: 24449267
pmcid: 3909793
doi: 10.1101/gad.235184.113
Soto-Gamez A, Quax WJ, Demaria M. Regulation of survival networks in senescent cells: from mechanisms to interventions. J Mol Biol. 2019;431:2629–43.
pubmed: 31153901
doi: 10.1016/j.jmb.2019.05.036
Foster DA, Yellen P, Xu L, Saqcena M. Regulation of G1 cell cycle progression: distinguishing the restriction point from a nutrient-sensing cell growth checkpoint(s). Genes Cancer. 2010;1:1124–31.
pubmed: 21779436
pmcid: 3092273
doi: 10.1177/1947601910392989
Campisi J. The biology of replicative senescence. Eur J Cancer. 1997;33:703–9.
Sager R. Senescence as a mode of tumor suppression. Environ Health Perspect. 1991;93:59–62.
pubmed: 1663451
pmcid: 1568048
doi: 10.1289/ehp.919359
Muñoz-Espín D, Serrano M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol. 2014;15:482–96.
pubmed: 24954210
doi: 10.1038/nrm3823
Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175–93.
pubmed: 30655609
pmcid: 7325303
doi: 10.1038/s41580-018-0089-8
Childs BG, Baker DJ, Kirkland JL, Campisi J, van Deursen JM. Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep. 2014;15:1139–53.
pubmed: 25312810
pmcid: 4253488
doi: 10.15252/embr.201439245
Wang B, Kohli J, Demaria M. Senescent cells in cancer therapy: friends or foes? Trends Cancer. 2020;6:838–57.
Milanovic M, Fan DNY, Belenki D, Däbritz JHM, Zhao Z, Yu Y, et al. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018;553:96–100.
pubmed: 29258294
doi: 10.1038/nature25167
Lee S, Schmitt CA. The dynamic nature of senescence in cancer. Nat Cell Biol. 2019;21:94–101.
pubmed: 30602768
doi: 10.1038/s41556-018-0249-2
Saleh T, Tyutyunyk-Massey L, Murray GF, Alotaibi MR, Kawale AS, Elsayed Z, et al. Tumor cell escape from therapy-induced senescence. Biochem Pharm. 2019;162:202–12.
pubmed: 30576620
doi: 10.1016/j.bcp.2018.12.013
Crowe EP, Nacarelli T, Bitto A, Lerner C, Sell C, Torres C. Detecting senescence: methods and approaches. Methods Mol Biol. 2014;1170:425–45.
pubmed: 24906328
doi: 10.1007/978-1-4939-0888-2_23
Yegorov YE, Chernov DN, Akimov SS, Akhmalisheva AK, Smirnova YB, Shinkarev DB, et al. Blockade of telomerase function by nucleoside analogs. Biochem (Mosc). 1997;62:1296–305.
Severino J, Allen RG, Balin S, Balin A, Cristofalo VJ. Is beta-galactosidase staining a marker of senescence in vitro and in vivo? Exp Cell Res. 2000;257:162–71.
pubmed: 10854064
doi: 10.1006/excr.2000.4875
Yang NC, Hu ML. The limitations and validities of senescence associated-beta-galactosidase activity as an aging marker for human foreskin fibroblast Hs68 cells. Exp Gerontol. 2015;40:813–9.
doi: 10.1016/j.exger.2005.07.011
Salmonowicz H, Passos JF. Detecting senescence: a new method for an old pigment. Aging Cell. 2017;16:432–4.
pubmed: 28185406
pmcid: 5418201
doi: 10.1111/acel.12580
Dreesen O, Ong PF, Chojnowski A, Colman A. The contrasting roles of lamin B1 in cellular aging and human disease. Nucleus. 2013;4:283–90.
pubmed: 23873483
pmcid: 3810336
doi: 10.4161/nucl.25808
Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol. 1998;153:1741–8.
pubmed: 9846965
pmcid: 1866324
doi: 10.1016/S0002-9440(10)65689-1
Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88:593–602.
pubmed: 9054499
doi: 10.1016/S0092-8674(00)81902-9
Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006;444:638–42.
pubmed: 17136094
doi: 10.1038/nature05327
Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319:1352–5.
pubmed: 18323444
doi: 10.1126/science.1140735
Mooi WJ, Peeper D. Oncogene-induced cell senescence–halting on the road to cancer. N. Engl J Med. 2006;355:1037–46.
pubmed: 16957149
doi: 10.1056/NEJMra062285
Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 2014;14:359–70.
pubmed: 24739573
pmcid: 4049238
doi: 10.1038/nrc3711
Santinon G, Brian I, Pocaterra A, Romani P, Franzolin E, Rampazzo C, et al. dNTP metabolism links mechanical cues and YAP/TAZ to cell growth and oncogene-induced senescence. EMBO J. 2018;37:e97780.
pubmed: 29650681
pmcid: 5983219
doi: 10.15252/embj.201797780
DiMauro T, David G. Ras-induced senescence and its physiological relevance in cancer. CCDT. 2010;10:869–446.
doi: 10.2174/156800910793357998
Serrano I, McDonald PC, Lock F, Muller WJ, Dedhar S. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nat Commun. 2013;4:2976.
pubmed: 24356468
doi: 10.1038/ncomms3976
Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, et al. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep. 2013;3:1252–65.
pubmed: 23562156
doi: 10.1016/j.celrep.2013.03.004
Kaplon J, Zheng L, Meissl K, Chaneton B, Selivanov VA, Mackay G, et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature. 2013;498:109–12.
pubmed: 23685455
doi: 10.1038/nature12154
Hernandez-Segura A, de Jong TV, Melov S, Guryev V, Campisi J, Demaria M. Unmasking transcriptional heterogeneity in senescent cells. Curr Biol. 2017;27:2652–2660.e4.
pubmed: 28844647
pmcid: 5788810
doi: 10.1016/j.cub.2017.07.033
Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C, et al. Cellular senescence: defining a path forward. Cell. 2019;179:813–27.
pubmed: 31675495
doi: 10.1016/j.cell.2019.10.005
Johnsen JI, Dyberg C, Wickström M. Neuroblastoma-A neural crest derived embryonal malignancy. Front Mol Neurosci. 2019;12:9.
pubmed: 30760980
pmcid: 6361784
doi: 10.3389/fnmol.2019.00009
Brodeur GM. Spontaneous regression of neuroblastoma. Cell Tissue Res. 2018;372:277–86.
pubmed: 29305654
pmcid: 5920563
doi: 10.1007/s00441-017-2761-2
Cohn SL, Pearson ADJ, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) Classification System: an INRG task force report. J Clin Oncol. 2009;27:289–97.
pubmed: 19047291
pmcid: 2650388
doi: 10.1200/JCO.2008.16.6785
Maris JM. Recent advances in neuroblastoma. N. Engl J Med. 2010;362:2202–11.
pubmed: 20558371
pmcid: 3306838
doi: 10.1056/NEJMra0804577
Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, et al. Neuroblastoma. Nat Rev Dis Prim. 2016;2:16078.
pubmed: 27830764
doi: 10.1038/nrdp.2016.78
Brady SW, Liu Y, Ma X, Gout AM, Hagiwara K, Zhou X, et al. Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. Nat Commun. 2020;11:1–13.
Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, et al. A mechanistic classification of clinical phenotypes in neuroblastoma. Science. 2018;362:1165–70.
pubmed: 30523111
pmcid: 7875194
doi: 10.1126/science.aat6768
Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, et al. Genomic amplifications and distal 6q loss: novel markers for poor survival in high-risk neuroblastoma patients. J Natl Cancer Inst. 2018;110:1084–93.
pubmed: 29514301
pmcid: 6186524
doi: 10.1093/jnci/djy022
Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med. 1995;1:249–55.
pubmed: 7585042
doi: 10.1038/nm0395-249
Valentijn LJ, Koster J, Haneveld F, Aissa RA, Sluis P, Broekmans ME. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci USA. 2012;109:19190–5.
Clynes D, Higgs DR, Gibbons RJ. The chromatin remodeller ATRX: a repeat offender in human disease. Trends Biochem Sci. 2013;38:461–6.
pubmed: 23916100
doi: 10.1016/j.tibs.2013.06.011
Clynes D, Jelinska C, Xella B, Ayyub H, Scott C, Mitson M, et al. Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX. Nat Commun. 2015;6:7538.
pubmed: 26143912
doi: 10.1038/ncomms8538
Samy M, Gattolliat C-H, Pendino F, Hillion J, Nguyen E, Bombard S, et al. Loss of the malignant phenotype of human neuroblastoma cells by a catalytically inactive dominant-negative hTERT mutant. Mol Cancer Ther. 2012;11:2384–93.
pubmed: 22933702
doi: 10.1158/1535-7163.MCT-12-0281
Hansford LM, Thomas WD, Keating JM, Burkhart CA, Peaston AE, Norris MD, et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci USA. 2004;101:12664–9.
pubmed: 15314226
pmcid: 515113
doi: 10.1073/pnas.0401083101
Calao M, Sekyere EO, Cui HJ, Cheung BB, Thomas WD, Keating J, et al. Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation. Oncogene. 2013;32:3616–26.
pubmed: 22907436
doi: 10.1038/onc.2012.368
De Wyn J, Zimmerman MW, Weichert-Leahey N, Nunes C, Cheung BB, Abraham BJ, et al. MEIS2 is an adrenergic core regulatory transcription factor involved in early initiation of TH-MYCN-driven neuroblastoma formation. Cancers. 2021;13:4783.
pubmed: 34638267
pmcid: 8508013
doi: 10.3390/cancers13194783
Yakushiji-Kaminatsui N, Kondo T, Hironaka K-I, Sharif J, Endo TA, Nakayama M, et al. Variant PRC1 competes with retinoic acid-related signals to repress Meis2 in the mouse distal forelimb bud. Development. 2018;145:dev166348.
pubmed: 30190278
doi: 10.1242/dev.166348
Rickman DS, Schulte JH, Eilers M. The expanding world of N-MYC-driven tumors. Cancer Discov. 2018;8:150–63.
pubmed: 29358508
doi: 10.1158/2159-8290.CD-17-0273
Zanotti S, Vanhauwaert S, Van Neste C, Olexiouk V, Van Laere J, Verschuuren M, et al. MYCN-induced nucleolar stress drives an early senescence-like transcriptional program in hTERT-immortalized RPE cells. Sci Rep. 2021;11:14454.
pubmed: 34262099
pmcid: 8280219
doi: 10.1038/s41598-021-93863-9
Turi Z, Lacey M, Mistrik M, Moudry P. Impaired ribosome biogenesis: mechanisms and relevance to cancer and aging. Aging. 2019;11:2512–40.
pubmed: 31026227
pmcid: 6520011
doi: 10.18632/aging.101922
Boon K, Caron HN, van Asperen R, Valentijn L, Hermus M-C, van Sluis P, et al. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J. 2001;20:1383–93.
pubmed: 11250904
pmcid: 145518
doi: 10.1093/emboj/20.6.1383
Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992;69:119–28.
pubmed: 1555236
doi: 10.1016/0092-8674(92)90123-T
Steiner P, Philipp A, Lukas J, Godden-Kent D, Pagano M, Mittnacht S, et al. Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J. 1995;14:4814–26.
pubmed: 7588611
pmcid: 394579
doi: 10.1002/j.1460-2075.1995.tb00163.x
Pérez-Roger I, Solomon DL, Sewing A, Land H. Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes. Oncogene. 1997;14:2373–81.
pubmed: 9188852
doi: 10.1038/sj.onc.1201197
Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318:533–8.
pubmed: 3906410
doi: 10.1038/318533a0
Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF–Mdm2–p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13:2658–69.
pubmed: 10541552
pmcid: 317106
doi: 10.1101/gad.13.20.2658
Jäger R, Herzer U, Schenkel J, Weiher H. Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice. Oncogene. 1997;15:1787–95.
pubmed: 9362445
doi: 10.1038/sj.onc.1201353
Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell. 2002;109:321–34.
pubmed: 12015982
doi: 10.1016/S0092-8674(02)00738-9
Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 1983;304:596–602.
pubmed: 6308472
doi: 10.1038/304596a0
Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell. 1987;49:465–75.
pubmed: 3032456
doi: 10.1016/0092-8674(87)90449-1
Carnero A, Beach DH. Absence of p21WAF1 cooperates with c-myc in bypassing Ras-induced senescence and enhances oncogenic cooperation. Oncogene. 2004;23:6006–11.
pubmed: 15195145
doi: 10.1038/sj.onc.1207839
Zhuang D, Mannava S, Grachtchouk V, Tang W-H, Patil S, Wawrzyniak JA, et al. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene. 2008;27:6623–34.
pubmed: 18679422
doi: 10.1038/onc.2008.258
Juin P, Hueber A-O, Littlewood T, Evan G. c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev. 1999;13:1367–81.
pubmed: 10364155
pmcid: 316765
doi: 10.1101/gad.13.11.1367
Fulda S, Lutz W, Schwab M, Debatin KM. MycN sensitizes neuroblastoma cells for drug-triggered apoptosis. Med Pediatr Oncol. 2000;35:582–4.
pubmed: 11107122
doi: 10.1002/1096-911X(20001201)35:6<582::AID-MPO19>3.0.CO;2-2
Grandori C, Wu K-J, Fernandez P, Ngouenet C, Grim J, Clurman BE, et al. Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev. 2003;17:1569–74.
pubmed: 12842909
pmcid: 196129
doi: 10.1101/gad.1100303
Robinson K, Asawachaicharn N, Galloway DA, Grandori C. c-Myc accelerates S-phase and requires WRN to avoid replication stress. PLoS ONE. 2009;4:e5951.
pubmed: 19554081
pmcid: 2694031
doi: 10.1371/journal.pone.0005951
Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D, et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol. 2010;12:54–9. sup pp 1-14
pubmed: 20010815
doi: 10.1038/ncb2004
Reimann M, Lee S, Loddenkemper C, Dörr JR, Tabor V, Aichele P, et al. Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell. 2010;17:262–72.
pubmed: 20227040
doi: 10.1016/j.ccr.2009.12.043
Hsu C-H, Altschuler SJ, Wu LF. Patterns of early p21 dynamics determine proliferation-senescence cell fate after chemotherapy. Cell 2019;178:361–373.e12.
pubmed: 31204100
pmcid: 6688629
doi: 10.1016/j.cell.2019.05.041
Albihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res. 2010;107:163–224.
pubmed: 20399964
doi: 10.1016/S0065-230X(10)07006-5
Mundo L, Ambrosio MR, Raimondi F, Del Porro L, Guazzo R, Mancini V, et al. Molecular switch from MYC to MYCN expression in MYC protein negative Burkitt lymphoma cases. Blood Cancer J. 2019;9:91.
pubmed: 31748534
pmcid: 6868231
doi: 10.1038/s41408-019-0252-2
Smith K, Dalton S. Myc transcription factors: key regulators behind establishment and maintenance of pluripotency. Regen Med. 2010;5:947–59.
pubmed: 21082893
doi: 10.2217/rme.10.79
Nesbit CE, Grove LE, Yin X, Prochownik EV. Differential apoptotic behaviors of c-myc, N-myc, and L-myc oncoproteins. Cell Growth Differ. 1998;9:731–41.
pubmed: 9751117
Kholodenko IV, Kalinovsky DV, Doronin II, Deyev SM, Kholodenko RV. Neuroblastoma origin and therapeutic targets for immunotherapy. J Immunol Res. 2018;2018:7394268.
pubmed: 30116755
pmcid: 6079467
doi: 10.1155/2018/7394268
te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002;62:1876–83.
Saleh T, Bloukh S, Carpenter VJ, Alwohoush E, Bakeer J, Darwish S, et al. Therapy-induced senescence: an ‘old’ friend becomes the enemy. Cancers. 2020;12:E822.
pubmed: 32235364
doi: 10.3390/cancers12040822
Liang X, Wu Q, Luan S, Yin Z, He C, Yin L, et al. A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade. Eur J Med Chem. 2019;171:129–68.
pubmed: 30917303
doi: 10.1016/j.ejmech.2019.03.034
Taschner-Mandl S, Schwarz M, Blaha J, Kauer M, Kromp F, Frank N, et al. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence. Oncotarget. 2016;7:3571–86.
pubmed: 26657295
doi: 10.18632/oncotarget.6527
Ryl T, Kuchen EE, Bell E, Shao C, Flórez AF, Mönke G, et al. Cell-cycle position of single MYC-driven cancer cells dictates their susceptibility to a chemotherapeutic drug. Cell Syst. 2017;5:237–250.e8.
pubmed: 28843484
doi: 10.1016/j.cels.2017.07.005
Bojko A, Czarnecka-Herok J, Charzynska A, Dabrowski M, Sikora E. Diversity of the senescence phenotype of cancer cells treated with chemotherapeutic agents. Cells 2019;8:E1501.
pubmed: 31771226
doi: 10.3390/cells8121501
Narath R, Ambros IM, Kowalska A, Bozsaky E, Boukamp P, Ambros PF. Induction of senescence in MYCN amplified neuroblastoma cell lines by hydroxyurea. Genes Chromosomes Cancer. 2007;46:130–42.
pubmed: 17106870
doi: 10.1002/gcc.20393
Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16:145–54.
pubmed: 32066940
doi: 10.1038/s41584-020-0373-9
Baluapuri A, Wolf E, Eilers M. Target gene-independent functions of MYC oncoproteins. Nat Rev Mol Cell Biol. 2020;21:255–67.
pubmed: 32071436
pmcid: 7611238
doi: 10.1038/s41580-020-0215-2
Büchel G, Carstensen A, Mak K-Y, Roeschert I, Leen E, Sumara O, et al. Association with Aurora-A controls N-MYC-dependent promoter escape and pause release of RNA polymerase II during the cell cycle. Cell Rep. 2017;21:3483–97.
pubmed: 29262328
pmcid: 5746598
doi: 10.1016/j.celrep.2017.11.090
Sells TB, Chau R, Ecsedy JA, Gershman RE, Hoar K, Huck J, et al. MLN8054 and Alisertib (MLN8237): discovery of selective oral Aurora A inhibitors. ACS Med Chem Lett. 2015;6:630–4.
pubmed: 26101564
pmcid: 4468408
doi: 10.1021/ml500409n
Yang Y, Ding L, Zhou Q, Fen L, Cao Y, Sun J, et al. Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells. Cancer Cell Int. 2020;20:9.
pubmed: 31920463
pmcid: 6947931
doi: 10.1186/s12935-019-1072-y
Azuhata T, Scott D, Takamizawa S, Wen J, Davidoff A, Fukuzawa M, et al. The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J Pediatr Surg. 2001;36:1785–91.
pubmed: 11733907
doi: 10.1053/jpsu.2001.28839
Lamers F, van der Ploeg I, Schild L, Ebus ME, Koster J, Hansen BR, et al. Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. Endocr Relat Cancer. 2011;18:657–68.
pubmed: 21859926
doi: 10.1530/ERC-11-0207
Bogen D, Wei JS, Azorsa DO, Ormanoglu P, Buehler E, Guha R, et al. Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma. Oncotarget 2015;6:35247–62.
pubmed: 26497213
pmcid: 4742102
doi: 10.18632/oncotarget.6208
Moreno L, Barone G, DuBois SG, Molenaar J, Fischer M, Schulte J, et al. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. Eur J Cancer. 2020;136:52–68.
pubmed: 32653773
doi: 10.1016/j.ejca.2020.05.010
Sun M, Veschi V, Bagchi S, Xu M, Mendoza A, Liu Z, et al. Targeting the chromosomal passenger complex subunit INCENP induces polyploidization, apoptosis and senescence in neuroblastoma. Cancer Res. 2019;79:4937–50.
pubmed: 31416840
pmcid: 6774870
doi: 10.1158/0008-5472.CAN-19-0695
Poratti M, Marzaro G. Third-generation CDK inhibitors: a review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib. Eur J Med Chem. 2019;172:143–53.
pubmed: 30978559
doi: 10.1016/j.ejmech.2019.03.064
Dreidax D, Bannert S, Henrich K-O, Schröder C, Bender S, Oakes CC, et al. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas. Hum Mol Genet. 2014;23:6826–37.
pubmed: 25104850
doi: 10.1093/hmg/ddu406
Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013;19:6173–82.
pubmed: 24045179
doi: 10.1158/1078-0432.CCR-13-1675
Ross RA, Spengler BA, Biedler JL. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst. 1983;71:741–7.
pubmed: 6137586
Wainwright LJ, Lasorella A, Iavarone A. Distinct mechanisms of cell cycle arrest control the decision between differentiation and senescence in human neuroblastoma cells. Proc Natl Acad Sci USA. 2001;98:9396–400.
pubmed: 11481496
pmcid: 55432
doi: 10.1073/pnas.161288698
Jauhari A, Singh T, Pandey A, Singh P, Singh N, Srivastava AK, et al. Differentiation induces dramatic changes in miRNA profile, where loss of dicer diverts differentiating SH-SY5Y cells toward senescence. Mol Neurobiol. 2017;54:4986–95.
pubmed: 27525675
doi: 10.1007/s12035-016-0042-9
Squillaro T, Alessio N, Cipollaro M, Melone MAB, Hayek G, Renieri A, et al. Reduced expression of MECP2 affects cell commitment and maintenance in neurons by triggering senescence: new perspective for Rett syndrome. Mol Biol Cell. 2012;23:1435–45.
pubmed: 22357617
pmcid: 3327309
doi: 10.1091/mbc.e11-09-0784
Salloum R, Hummel TR, Kumar SS, Dorris K, Li S, Lin T, et al. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. J Neurooncol. 2016;129:443–51.
pubmed: 27350411
pmcid: 5288808
doi: 10.1007/s11060-016-2189-7
Hosoi T, Nakatsu K, Shimamoto A, Tahara H, Ozawa K. Inhibition of telomerase causes vulnerability to endoplasmic reticulum stress-induced neuronal cell death. Neurosci Lett. 2016;629:241–4.
pubmed: 27443785
doi: 10.1016/j.neulet.2016.07.027
Edelman MJ, Lapidus R, Feliciano J, Styblo M, Beumer JH, Liu T, et al. Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors. Cancer Chemother Pharm. 2016;78:959–67.
doi: 10.1007/s00280-016-3148-x
Sugarman ET, Zhang G, Shay JW. In perspective: an update on telomere targeting in cancer. Mol Carcinog. 2019;58:1581–8.
pubmed: 31062416
pmcid: 6692182
doi: 10.1002/mc.23035
Tong AS, Stern JL, Sfeir A, Kartawinata M, de Lange T, Zhu X-D, et al. ATM and ATR signaling regulate the recruitment of human telomerase to telomeres. Cell Rep. 2015;13:1633–46.
pubmed: 26586433
pmcid: 4662887
doi: 10.1016/j.celrep.2015.10.041
Flynn RL, Cox KE, Jeitany M, Wakimoto H, Bryll AR, Ganem NJ, et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science. 2015;347:273–7.
pubmed: 25593184
pmcid: 4358324
doi: 10.1126/science.1257216
Foote KM, Nissink JWM, McGuire T, Turner P, Guichard S, Yates JWT, et al. Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent. J Med Chem. 2018;61:9889–907.
pubmed: 30346772
doi: 10.1021/acs.jmedchem.8b01187
George SL, Parmar V, Lorenzi F, Marshall LV, Jamin Y, Poon E, et al. Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma. J Exp Clin Cancer Res. 2020;39:78.
pubmed: 32375866
pmcid: 7201617
doi: 10.1186/s13046-020-01582-2
Coppé J-P, Desprez P-Y, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118.
pubmed: 20078217
pmcid: 4166495
doi: 10.1146/annurev-pathol-121808-102144
Dörr JR, Yu Y, Milanovic M, Beuster G, Zasada C, Däbritz JHM, et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature. 2013;501:421–5.
pubmed: 23945590
doi: 10.1038/nature12437
Correia-Melo C, Marques FDM, Anderson R, Hewitt G, Hewitt R, Cole J, et al. Mitochondria are required for pro-ageing features of the senescent phenotype. EMBO J. 2016;35:724–42.
pubmed: 26848154
pmcid: 4818766
doi: 10.15252/embj.201592862
Roberson RS, Kussick SJ, Vallieres E, Chen S-YJ, Wu DY. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res. 2005;65:2795–803.
pubmed: 15805280
doi: 10.1158/0008-5472.CAN-04-1270
Wang Q, Wu PC, Roberson RS, Luk BV, Ivanova I, Chu E, et al. Survivin and escaping in therapy-induced cellular senescence. Int J Cancer. 2011;128:1546–58.
pubmed: 20503268
doi: 10.1002/ijc.25482
Capalbo G, Rödel C, Stauber RH, Knauer SK, Bache M, Kappler M, et al. The role of survivin for radiation therapy. Strahlenther Onkol. 2007;183:593–9.
pubmed: 17960333
doi: 10.1007/s00066-007-1800-4
Engels K, Knauer SK, Metzler D, Simf C, Struschka O, Bier C, et al. Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol. 2007;211:532–40.
pubmed: 17334981
doi: 10.1002/path.2134
Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998;351:882–3.
pubmed: 9525374
doi: 10.1016/S0140-6736(05)70294-4
McKenzie PP, Danks MK, Kriwacki RW, Harris LC. P21Waf1/Cip1 dysfunction in neuroblastoma: a novel mechanism of attenuating G0-G1 cell cycle arrest. Cancer Res. 2003;63:3840–4.
pubmed: 12839982
Decaesteker B, Denecker G, Van Neste C, Dolman EM, Van Loocke W, Gartlgruber M, et al. TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets. Nat Commun. 2018;9:4866.
pubmed: 30451831
pmcid: 6242972
doi: 10.1038/s41467-018-06699-9
Jacobs JJ, Keblusek P, Robanus-Maandag E, Kristel P, Lingbeek M, Nederlof PM, et al. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat Genet. 2000;26:291–9.
pubmed: 11062467
doi: 10.1038/81583
Prince S, Carreira S, Vance KW, Abrahams A, Goding CR. Tbx2 directly represses the expression of the p21(WAF1) cyclin-dependent kinase inhibitor. Cancer Res. 2004;64:1669–74.
pubmed: 14996726
doi: 10.1158/0008-5472.CAN-03-3286
Bierbrauer A, Jacob M, Vogler M, Fulda S. A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma. Br J Cancer. 2020;122:1544–51.
pubmed: 32203216
pmcid: 7217842
doi: 10.1038/s41416-020-0795-9
Carpenter VJ, Saleh T, Gewirtz DA. Senolytics for cancer therapy: is all that glitters really gold? Cancers. 2021;13:723.
pubmed: 33578753
pmcid: 7916462
doi: 10.3390/cancers13040723